Vantis Vascular has filed a notice of an exempt offering of securities to raise $21,500,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Vantis Vascular is raising up to $21,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Vantis Vascular
Vantis Vascular is a physician-founded medical technology company that develops innovative devices to help vascular interventionalists confidently, safely, and efficiently treat complex cases. According to its website, the company focuses on performance-driven technology for vascular interventions, aiming to engineer a future in which clinicians can go faster and further during vascular procedures with the right tools. Vantis Vasculars solutions are designed specifically to address navigation and treatment challenges in complex, calcified, and tortuous anatomies, enhancing delivery, safety, and efficiency for coronary and peripheral interventions. Positioned as a pioneer of next-generation vascular technologies, the company emphasizes clinical excellence and close collaboration with physicians in the design of its products. Headquartered in San Jose, California, Vantis Vascular presents itself as a forward-looking partner for interventional specialists seeking advanced tools to improve procedural success and patient care.
To learn more, visit https://www.vantisvascular.com/
LinkedIn: https://www.linkedin.com/company/vantis-vascular
Contact:
Phillip Torrence, Secretary
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.